PD-L1降解途径与肿瘤免疫治疗  

PD-L1 Degradation Pathway and Cancer Immunotherapy

作　　者：李梦 朱成钢[1] LI Meng;ZHU Chenggang(College of Life Sciences,Zhejiang University,Hangzhou 310012,Zhejiang,China)

机构地区：[1]浙江大学生命科学学院,中国浙江杭州310012

出　　处：《生命科学研究》2023年第6期506-511,共6页Life Science Research

基　　金：国家自然科学基金资助项目(82151220)。

摘　　要：程序性死亡受体配体1(programmed death ligand 1,PD-L1)是肿瘤免疫检查点阻断治疗中的重要靶点,其在多种细胞中均有表达。肿瘤细胞可通过高表达PD-L1来增强程序性死亡受体1(programmed death 1,PD-1)抑制信号,从而促进肿瘤免疫逃逸。近年来,以抗PD-1/PD-L1抗体为代表的肿瘤免疫治疗给癌症治疗带来了革命性的变化。然而,肿瘤免疫治疗仅能对部分患者产生持久的疗效,多数患者对肿瘤免疫治疗的应答短暂或没有应答。研究发现,PD-L1的降解对肿瘤免疫治疗应答至关重要。本文综述了PD-L1的溶酶体降解途径、蛋白酶体降解途径及PD-L1降解与肿瘤免疫治疗的相互作用,旨在为进一步增强肿瘤免疫治疗的应答率和应答范围提供研究思路。Programmed death ligand 1(PD-L1)has emerged as an important target in immune checkpoint blockade therapy for cancer.It is expressed in a variety of cells.Its high expression in tumor cells can enhance programmed death 1(PD-1)inhibitory signals,thus promoting tumor immune escape.In recent years,cancer immunotherapy based on anti-PD-1/PD-L1 antibodies has brought revolutionary changes in cancer treatment.However,cancer immunotherapy produces long-lasting treatment effects only in some people with cancer.For most patients,it has short-term or no effects.Studies have found that the degradation of PD-L1 is critical for treatment response to cancer immunotherapy.Herein,the lysosomal and proteasomal pathways of PD-L1 degradation and the interaction of PD-L1 degradation with cancer immunotherapy are reviewed,

关 键 词：程序性死亡受体配体1(PD-L1) 溶酶体降解途径 蛋白酶体降解途径 肿瘤免疫治疗 

分 类 号：Q513[生物学—生物化学] R730.51[医药卫生—肿瘤]